CVR 32879861Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)København KFounded 19 Apr 2010
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Vesper Bio ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
8
CVR, Aug 2026
0 (0%) over 12 months
Gross profit
-36.4M
DKK, annual report 2025
Result
-48.2M
DKK, annual report 2025
Equity
-227.4M
DKK, annual report 2025
LUNDBECKFONDENCVR 11814913, 66.7% to under 90% of capital and votes, since 30 May 2013
75PMK Holding ApSCVR 26346185, 20% to under 25% of capital and votes, since 19 Apr 2010
Operating company
Dandex estimate: 8 employees registered in 2026Jacob Falck Hansensince 25 Jun 2025
CVR 2634618520% to under 25% of capital and votesclass Anotified 15 Dec 2017since 19 Apr 2010
CVR 1181491366.7% to under 90% of capital and votesclass Bnotified 25 Sep 2015since 30 May 2013
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
Decided by Dandex with fixed rules from CVR and the filed annual reports, not registered by the company. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
19 Apr 2010 to 12 Nov 2026.
Aug 2026, monthly: 8 employees, 7 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 9 | 8 | 7 | 7 | 7 | 9 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| FTE | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 6 | 5 | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 9 | 8 | 9 | 10 | 9 | 10 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 9 | 7 | 7 | 7 | 7 | 8 | 7 | 8 | 7 | 8 | 8 | 8 | 7 | 7 |
| Series | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Annual 2013 to 2014; monthly Jan 2015 to Aug 2026.
CVR changed its monthly method in Oct 2019, so a step at that month need not be real.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -13,499 | -31,620 | -67,586 | -67,244 | -36,446 |
| Operating profit | -14,946 | -32,959 | -71,994 | -72,836 | -42,491 |
| Result for the year | -16,471 | -36,860 | -52,563 | -66,506 | -48,201 |
| Equity | -23,303 | -60,163 | -112,726 | -179,232 | -227,433 |
| Total assets | 5,275 | 25,532 | 32,181 | 69,849 | 65,946 |
| Employees (average) | 0 | 1 | 6 | 9 | 8 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | -100% | 0% | 500% | 50% | -11.1% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 12 Mar 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 15 May 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 5 Mar 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 27 Mar 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 17 Mar 2022
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For Vesper Bio ApS, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
From CVR, read 12 Nov 2026. Text such as the signing rule and purpose is shown as registered.
18 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Direktion:
Fratrådte:
Paul Brian Little, (adm. dir), den 25.06.2025.
Tiltrådte:
Jacob Falck Hansen, (adm. dir), den 25.06.2025.
Ny adresse: Hauser Plads 10, 4., 1127 København K
Ny adresse: c/o Lydens Hus, Gammel Kongevej 11, 1., 1610 København V
Vedtægter ændret: 10.11.2023
Nyt navn: Vesper Bio ApS
Slettede binavne: INSUSENSE THERAPEUTICS ApS, Vesper Bio ApS
Vedtægter ændret: 25.05.2021
Nye binavne: Vesper Bio ApS, Vesper Biotechnology ApS
Slettede binavne: DIABETICON ApS, INSUSENSE BIOPHARMA ApS, INSUSENSE BIOPHARMACEUTICALS ApS, INSUSENSE PHARMA ApS, INSUSENSE PHARMACEUTICALS ApS
Formål ændret: Selskabets formål er at drive forsknings- og udviklingsvirksomhed rettet mod udvikling af lægemidler til behandling af hjernesygdomme, diabetes, diabetes-relaterede metaboliske, sygdomme, fedme og/eller fedmerelaterede sygdomme, samt at udføre aktiviteter, der er forbundet hermed.
Vedtægter ændret: 25.05.2021
Nye binavne: Vesper Bio ApS, Vesper Biotechnology ApS
Slettede binavne: DIABETICON ApS, INSUSENSE BIOPHARMA ApS, INSUSENSE BIOPHARMACEUTICALS ApS, INSUSENSE PHARMA ApS, INSUSENSE PHARMACEUTICALS ApS
Formål ændret: Selskabets formål er at drive forsknings- og udviklingsvirksomhed rettet mod udvikling af lægemidler til behandling af hjernesygdomme, diabetes, diabetes-relaterede metaboliske, sygdomme, fedme og/eller fedmerelaterede sygdomme, samt at udføre aktiviteter, der er forbundet hermed.
Direktion:
Fratrådte:
Christian Ellebæk Elling (adm. dir), den 30.09.2018.
Tiltrådte:
Paul Brian Little (adm. dir), den 01.10.2018.
Vedtægter ændret: 15.12.2017
Kapitalforhøjelsen er besluttet den 15.12.2017.
kr. 66.741,00, indbetalt kontant, kurs 11.237,47.
Kapitalen udgør herefter kr. 355.952,00.
Vedtægter ændret: 25.09.2015
Kapitalforhøjelse: kr. 66.741,00, indbetalt kontant, kurs 11.237,47.
Kapitalen udgør herefter kr. 289.211,00.
Ny adresse:
c/o Lundbeckfonden, Scherfigsvej 7, 2100 København Ø.
Ny kommune:
København.
Vedtægter ændret:
28.10.2013.
Nye binavne:
INSUSENSE BIOPHARMA ApS, INSUSENSE BIOPHARMACEUTICALS ApS, INSUSENSE PHARMA ApS, INSUSENSE PHARMACEUTICALS ApS, INSUSENSE THERAPEUTICS ApS.
Revision:
Udtrådt af revisionen:
CVR-NR. 25821939 HENRICHSEN & CO, STATSAUTORISERET REVISIONSAKTIESELSKAB, den 01.08.2013.
Indtrådt i revisionen:
BEIERHOLM, STATSAUTORISERET REVISIONSPARTNERSELSKAB, Gribskovvej 2, 2100 København Ø, den 01.08.2013.
Revision:
Udtrådt af revisionen:
BRANDT STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 01.07.2013.
Indtrådt i revisionen:
CVR-NR. 25821939 HENRICHSEN & CO, STATSAUTORISERET REVISIONSAKTIESELSKAB, Wildersgade 10B, 1408 København K, den 01.07.2013.
Vedtægter ændret:
30.05.2013.
Kapitalforhøjelse:
kr. 133.482,00 indbetalt kontant, kurs 112,37.
Kapitalen udgør herefter kr. 222.470,00.
Kapitalen er opdelt i klasser:
A-anparter kr. 88.988,00. B-anparter kr. 133.482,00.
Direktion:
Udtrådt af direktionen:
Anders Nykjær, den 30.05.2013.
Indtrådt i direktionen:
Direktør Christian Ellebæk Elling (adm. dir), den 30.05.2013.
Vedtægter ændret:
04.01.2013.
Kapitalnedsættelse besluttet 04.01.2013 er gennemført 07.02.2013.
Kapitalen udgør herefter kr. 88.988,00.
Vedtægter ændret:
04.01.2013.
Binavn:
DIABETICON ApS.
Kapitalnedsættelse besluttet 04.01.2013 udbetaling til anpartshavere kr. 248.082,00 til kurs 100,00, henlæggelse til særlig reserve kr. 37.869,00 til kurs 100,00.
Selskabets kreditorer opfordres til at anmelde deres krav til selskabet. Kreditorerne kan kræve betryggende sikkerhed for uforfaldne krav og betaling af forfaldne krav. Krav skal anmeldes senest 4 uger fra dags dato.
Selskabet tegnes af 1 direktør alene.
Revision:
Udtrådt af revisionen:
Revisionsfirma Svendsen & Sørensen I/S, den 01.01.2012.
Indtrådt i revisionen:
BRANDT STATSAUTORISERET REVISIONSPARTNERSELSKAB, Vestergade 56 F, 8000 Aarhus C, den 01.01.2012.
Binavn:
DIABETICON ApS (INSUSENSE ApS).
Stiftelsesdato:
19.04.2010.
Seneste vedtægtsdato:
19.04.2010.
Kapital:
kr. 374.939,00.
Indbetalingsmåde:
kontant kr. 374.939,00 til kurs 118,67.
Stifter:
CVR-NR. 26346185 ANDERS NYKJÆR HOLDING ApS, Skolevangs Alle 1, b., 8240 Risskov, den 19.04.2010.
Direktion:
Anders Nykjær (adm. dir), den 19.04.2010.
Selskabet tegnes af en direktør eller af den samlede direktion.
Revision:
Revisionsfirma Svendsen & Sørensen I/S, Vestergade 56 F, 8000 Århus C, den 19.04.2010.
Første regnskabsår:
19.04.2010 - 31.12.2010.
Regnskabsår:
01.01 - 31.12.
1 registered in CVR.
P-number 1015994513Hauser Plads 10, 1127 København K
